新活素辅助贝那普利对中重度心力衰竭患者炎性因子与BNP水平的影响研究  

The Effect of Neovitrin Assisted Benazepril on the Levels of Inflammatory Factors and BNP in Patients with Moderate to Severe Heart Failure

作　　者：宓文珍 MI Wen-zhen(Liaocheng Infectious Disease Hospital,Liaocheng 252000,China)

机构地区：[1]聊城市传染病医院,山东聊城252000

出　　处：《中国医药指南》2020年第20期26-28,共3页Guide of China Medicine

摘　　要：目的探讨新活素辅助贝那普利对中重度心力衰竭患者炎性因子与BNP水平的影响。方法选取我院(2017年7月至2020年1月)收治的中重度HF患者100例,均表现为不同程度水肿、乏力、呼吸困难,根据不同治疗分为两组,对照组(n=50)接受贝那普利治疗,观察组(n=50)接受贝在对照组基础上接受新活素治疗,对比两组患者治疗前后NYHA分级和炎性因子[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平以及者心脏射血分数(EF)和脑钠肽(BNP)水平。结果治疗后观察组患者NYHA分级Ⅰ级、Ⅱ级、Ⅲ级、Ⅳ级分别为5例(10.00%)、33例(66.00%)、10例(20.00%)、2例(4.00%),对照组为2例(4.00%)、32例(64.00%)、13例(26.00%)、3例(6.00%),两组患者NYHA分级对比无差异(t=2.7650、0.0879、1.0164、0.4211,P> 0.05)。治疗后观察组hs-CRP(6.12±1.83)mg/L、IL-6为(22.56±6.19)ng/L、TNF-α(10.42±2.75)ng/L,治疗后对照组hs-CRP(8.64±1.75)mg/L、IL-6为(26.77±7.58)ng/L、TNF-α(12.14±3.68)ng/L,两组患者炎性因子水平对比差异明显(t=7.0373、3.0419、2.6474,P <0.05)。治疗后观察组EF值(57.76±15.52)%,BNP(1996.35±1028.56)pg/mL;治疗后对照组EF值(48.54±16.29)%,BNP(2637.54±1247.45)pg/mL。治疗后两组患者EF值和BNP水平对比差异明显(t=2.8976、2.8042,P <0.05)。两组患者均没有出现明显不良反应。结论新活素辅助贝那普利治疗中重度HF疗效显著,可有效改善心功能,控制炎性因子,降低HNP水平,值得推广。Objective To explore the effect of neovitrin-assisted benazepril on the levels of inflammatory factors and BNP in patients with moderate to severe heart failure.Methods 100 patients with moderate to severe HF who were admitted to our hospital(July 2017 to January 2020) were selected.They all showed different degrees of edema,fatigue,and dyspnea.They were divided into two groups according to different treatments,and the control group(n=50) Receive benazepril treatment,the observation group(n=50) receive beyzepril treatment based on the control group,compare the two groups of patients before and after treatment NYHA grade and inflammatory factors [high-sensitivity C-reactive protein(hs-CRP),Interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)] levels and heart ejection fraction(EF) and brain natriuretic peptide(BNP) levels.Results After treatment,the observation group patients had NYHA grades Ⅰ,Ⅱ,Ⅲ,and Ⅳ of 5 cases(10.00%),33 cases(66.00%),10 cases(20.00%),and 2 cases(4.00%),and the control group had 2 cases(4.00%),32 cases(64.00%),13 cases(26.00%),3 cases(6.00%),there was no difference in NYHA classification between the two groups(t=2.7650,0.0879,1.0164,0.4211,P>0.05).After treatment,the observation group hs-CRP(6.12±1.83)mg/L,IL-6 was(22.56±6.19)ng/L,TNF-α(10.42±2.75)ng/L,and the control group after treatment hs-CRP(8.64±1.75)mg/L,IL-6 was(26.77±7.58)ng/L,TNF-α(12.14±3.68)ng/L,the difference in inflammatory factor levels between the two groups was significant(t=7.0373,3.0419,2.6474,P<0.05).After treatment,the EF value of the observation group was(57.76±15.52)%,BNP(1996.35±1028.56)pg/mL;the EF value of the control group after treatment was(48.54±16.29)%,BNP(2637.54±1247.45)pg/mL.The difference in EF value and BNP level between the two groups after treatment was significant(t=2.8976,2.8042,P<0.05).There were no obvious adverse reactions in both groups.Conclusion Neovitrin-assisted benazepril is effective in the treatment of moderate and severe HF.It can effectively improve heart function,control

关 键 词：新活素 贝那普利 中重度心力衰竭 炎性因子 BNP 

分 类 号：R541.6[医药卫生—心血管疾病]